Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Media Clear all

Conditions: Age-Related Macular Degeneration
Interventions: Elamipretide; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Otitis Media, Antimicrobial Stewardship
Interventions: Device: Digital Otoscope; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
Interventions: Horyzons USA; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 35 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Pregnancy, Fertility
Interventions: Not listed
Lead sponsor: BioIncept LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peri-implant Mucositis
Interventions: glycine powder air-powered debridement, Ultrasonic instrumentation; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sleep, Sleep Hygiene
Interventions: Timed evening technology and digital media use (tablet use), no technology and digital media use (screen media use); Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 48 Months to 59 Months
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: Physical Activity and Dietary Health Promotion Program; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Lane, South Carolina

Conditions: Life Style
Interventions: Health Links + Leadership Training, Health Links; Behavioral
Lead sponsor: Colorado School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 2,175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Glucose Transporter Type 1 Deficiency Syndrome, Glut1 Deficiency Syndrome
Interventions: Triheptanoin; Drug
Lead sponsor: Juan Pascual; Other
Eligibility: 30 Months to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Autism Spectrum Disorders
Interventions: social skills therapy; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 35 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Skin Cancer
Interventions: Sun Safety Ink! Program, Attention Control; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,820 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Golden, Colorado

Conditions: Hematopoietic Stem Cell Transplantations
Interventions: autoRIC®; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Postoperative Pain
Interventions: No choice given, Choice given, Ibuprofen, Acetaminophen, Gabapentin, Morphine (low), Morphine (med), Morphine (high); Other · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Mental Health Wellness
Interventions: GUIDE; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Medium-chain Acyl-CoA Dehydrogenase Deficiency
Interventions: Triheptanoin; Drug
Lead sponsor: Jerry Vockley, MD, PhD; Other
Eligibility: 4 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV-1-infection
Interventions: 426c.Mod.Core-C4b 30 mcg, 426c.Mod.Core-C4b 100 mcg, 426c.Mod.Core-C4b 300 mcg, Placebo, BG505; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Otitis Media, Antimicrobial Stewardship
Interventions: Education with personalized performance feedback, Use of digital otoscope; Other · Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Major Depressive Disorder
Interventions: Low Dose Psilocybin, Placebo, Medium Dose Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: ASP1941, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Atrial Fibrillation, Atrial Flutter
Interventions: Not listed
Lead sponsor: Keesler Air Force Base Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Keesler Air Force Base, Mississippi

Conditions: Dry Age-related Macular Degeneration
Interventions: GT005; Drug
Lead sponsor: Gyroscope Therapeutics Limited; Industry
Eligibility: 55 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 45
States / cities: Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 41 more

Conditions: Moderate to Severe Allergic Asthma
Interventions: CYT003, Placebo; Biological
Lead sponsor: Cytos Biotechnology AG; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 21
States / cities: Los Angeles, Huntington Beach, San Jose, California • Walnut Creek, San Diego, Riverside, Fountain Valley, California • Colorado Springs, Denver, Colorado + 18 more

Conditions: Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions: Placebo, PIZV; Drug · Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 271 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 7
States / cities: Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Behavioral Intervention, Survey Administration, Interview; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 54 Years
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Memphis, Tennessee • Seattle, Washington

Search by objective public record fields.

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Digital Otoscopy Versus Standard Otoscopy on the Diagnosis and Treatment of Otitis Media in Young Children

Horyzons: Implementation and Integration in Clinical Practice

Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome

Impact of Glycine Therapy on Peri-implant Mucositis

The Goodnight Screen Media Study

Effectiveness of a Church-Based Program at Increasing Physical Activity and Healthy Dietary Habits in African Americans

Small+Safe+Well: A Longitudinal Study of TWH in Small Business

Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)

The Multi-Media Social Skills Project for Adults

Sun Safety Ink! A Sun Safety Program for the Tattoo Community

Remote Ischemic Conditioning in HSCT

Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management

Testing a Wellness App for First Responders, Military Personnel and Veterans

Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD)

Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV

Digital Otoscope Versus Education and Feedback for Otitis Media in Young Children

Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder

A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus.

PREdicting Atrial Fibrillation or Flutter

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer